Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer
-
- Steger
- Creator
Journal
-
- Cancer Res
-
Cancer Res 69 (24), 564S-, 2009
Details
-
- CRID
- 1370283692562104457
-
- Data Source
-
- Crossref